Danish Drama: Genmab Drops $8B on Cancer Cure Hope Seller
In a move that screams 'we have billionaire money to burn,' Danish biotech bigwig Genmab announced it plans to acquire Merus, the brainiac behind a shiny new head and neck cancer drug, for around $8 billion. That's $8 billion, or roughly the cost of buying every Danish pastry in Copenhagen twice over. This deal lands Genmab firmly in Life Sciences prime, scheming to turn biology into cold, hard kroner. With cancer therapy innovation like this on the line, letâs hope Merus's drug fights neck and head tumors better than Genmab fought that price tag.
Share the Story
(1 of 3)Genmab just dropped $8 billion on Merus like itâs Black Friday for biotech, apparently 'saving cancer patients' is easier when you have a billionaire bankroll appearing out of nowhere.
Buying a head and neck cancer drug developer for $8 billion is peak pharmaceutical flexâGenmabâs basically saying, 'Weâll fix your cells, but first, show us the money.'
Genmab buying Merus is like paying $8 billion for a Tesla upgradeâyouâre still hoping it doesnât break down, but hey, it looks promising!
Source: Statnews | Published: 9/29/2025 | Author: Andrew Joseph
More Articles in Business
CIA Agents Accidentally Crash While Saving World, Constitution Possibly Breached
Trump Extends Ceasefire Because Iran's Drama Series Needs Another Season
FedEx, UPS, and DHL Embark on Epic Refund Quest, Customers Await Payback Like Lottery Winners
Tim Cook Steps Down, Apple Picks John Ternus Because 'Risk-Taking' Is Overrated
Apple Hands CEO Reins to Hardware Guy Who Says 'Logistics Are Cute, Look at This Widget'
American Grads Panic, Prefer DoorDash Over Dream Jobs, Blame AI(ish)
Amazon Instructs Vendors to Play Monopoly, Then Calls It Lawful Commerce
